Verizon CONTINUES Acceleration and 3 Stock Analyses Driving the Market

| + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

Ariad Pharmaceuticals Inc. (NASDAQ:ARIA): According to Rodman & Renshaw, the upward trend for Novartis’ chronic myelogenous leukemia drugs creates a positive read-through for the second-line CML treatment ponatinib from ARIAD (NASDAQ:ARIA). Rodman increased ARIAD’s price target to $22 but keeps its Market Outperform rating on the stock.

Don’t Miss: Did Verizon Just Drop A HINT About the New iPhone?

Verizon Communications Inc. (NYSE:VZ) valuation range has been raised by Wells Fargo following the company’s reports of in-line Q2 results. The firm predicts that the wireless results for the company have been strong, and it keeps its Outperform rating on the stock.

CSX Corp. (NYSE:CSX) was removed from Deutsche Bank’s short-term buy list.

Ocz Technology Group Inc. (NASDAQ:OCZ) mentioned on a Reuters report that HDD maker Seagate (NASDAQ:STX) has begun to consider purchasing OCZ, causing Piper Jaffray to believe that OCZ would complement HDD makers and NAND flash makers. Despite the outcome of any talks about buying, Piper believes that OCZ possesses several great opportunities. The firm keeps its Overweight rating on the stock.

Don’t Miss: How Did Apple Avoid CHAOS During iPad Debut in China?

Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.

More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business